Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-10

Clinical Trial Update: A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp [Phase 3]

View source ↗

Summary

Phase 3 trial completed evaluating the efficacy and safety of KX2-391 1% ointment for actinic keratoses on face or scalp.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KX2-391 Ointment 1%

Snippet

Sponsor: Almirall, S.A. | Conditions: Actinic Keratoses | Phase 3 | Status: COMPLETED | Results posted: 2021-03-10